Literature DB >> 23138184

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.

O G Ottmann, R A Larson, H M Kantarjian, P D le Coutre, M Baccarani, A Hochhaus, D W Kim, X Fan, S Novick, F J Giles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23138184     DOI： 10.1038/leu.2012.324

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors:  A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 2.  Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.

Authors:  Aaron Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Treat Options Oncol       Date:  2017-03

3.  Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.

Authors:  Adele K Fielding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 4.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

Review 5.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

Review 6.  Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Xavier Thomas; Maël Heiblig
Journal:  Int J Hematol Oncol       Date:  2016-09-23

7.  Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.

Authors:  Nitin Jain; Abhishek Maiti; Farhad Ravandi; Marina Konopleva; Naval Daver; Tapan Kadia; Naveen Pemmaraju; Nicholas Short; Partow Kebriaei; Jing Ning; Jorge Cortes; Elias Jabbour; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2021-05-28       Impact factor: 13.265

8.  Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia.

Authors:  Na Shen; Fei Yan; Jiuxia Pang; Na Zhao; Naseema Gangat; Laichu Wu; Ann M Bode; Aref Al-Kali; Mark R Litzow; Shujun Liu
Journal:  Clin Cancer Res       Date:  2017-07-18       Impact factor: 12.531

9.  Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.

Authors:  Afsar Ali Mian; Isabella Haberbosch; Hazem Khamaisie; Abed Agbarya; Larissa Pietsch; Elizabeh Eshel; Dally Najib; Claudia Chiriches; Oliver Gerhard Ottmann; Oliver Hantschel; Ricardo M Biondi; Martin Ruthardt; Jamal Mahajna
Journal:  Ann Hematol       Date:  2021-06-10       Impact factor: 3.673

10.  Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Authors:  V Bachanova; D I Marks; M-J Zhang; H Wang; M de Lima; M D Aljurf; M Arellano; A S Artz; U Bacher; J-Y Cahn; Y-B Chen; E A Copelan; W R Drobyski; R P Gale; J P Greer; V Gupta; G A Hale; P Kebriaei; H M Lazarus; I D Lewis; V A Lewis; J L Liesveld; M R Litzow; A W Loren; A M Miller; M Norkin; B Oran; J Pidala; J M Rowe; B N Savani; W Saber; R Vij; E K Waller; P H Wiernik; D J Weisdorf
Journal:  Leukemia       Date:  2013-08-30       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.